Sabby Management’s Editas Medicine EDIT Stock Holding History

Sabby Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-85,000	Closed	-$1.43M	–	186
2017 Q2	$1.43M	Sell	85,000 -5,300	-6%	-$95.5K	0.09%	87
2017 Q1	$2.02M	Sell	90,300 -24,700	-21%	-$512K	0.11%	91
2016 Q4	$1.87M	Sell	115,000 -20,000	-15%	-$304K	0.11%	107
2016 Q3	$1.82M	Buy	+135,000	New	+$2.77M	0.07%	138

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PVMCV

Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sabby Management's EDIT Position: Q3 2017 in Review

Sabby Management sold out of Editas Medicine (EDIT) in Q3 2017, closing a stake of 85,000 shares — an estimated $1.43M sold.

Sabby Management first reported a position in EDIT in Q3 2016 and held it in 4 quarters. The position peaked at $2.02M in Q1 2017. 116 funds tracked by Wall St. Rank hold EDIT as of Q3 2017.

Sabby Management reported no remaining Editas Medicine position as of Q3 2017 after selling out during the quarter.
Sabby Management sold 85,000 Editas Medicine shares in Q3 2017, an estimated $1.43M.
Sabby Management first reported a position in Editas Medicine in Q3 2016 and held it in 4 quarters.
Sabby Management's Editas Medicine position peaked at $2.02M in Q1 2017.
116 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.